Clinical Trial Update: Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Zibotentan in patients with intermittent claudication due to peripheral arterial disease; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Claudication
• Peripheral Arterial Disease

Drugs mentioned

• Zibotentan (zibotentan)

Snippet

Sponsor: University of Virginia | Conditions: Peripheral Arterial Disease, Intermittent Claudication | Phase 2 | Status: COMPLETED